M

MBX Biosciences Inc
NASDAQ:MBX

Watchlist Manager
MBX Biosciences Inc
NASDAQ:MBX
Watchlist
Price: 12.195 USD -1.89% Market Closed
Market Cap: 407.6m USD

Relative Value

There is not enough data to reliably calculate the relative value of MBX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MBX Relative Value
Base Case
Not Available
M
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.5
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-5.5
Industry
21.6
Forward
-4.5
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-6.2
Industry
16.7
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.1
Industry
24
vs History
33
vs Industry
Median 3Y
1.7
Median 5Y
1.7
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
12.9
Forward
-1.5
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
16.3
Forward
-1.5
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-2.4
Industry
15.2
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-2.4
Industry
17.7
vs History
33
vs Industry
Median 3Y
179.3
Median 5Y
179.3
Industry
1.9

Multiples Across Competitors

MBX Competitors Multiples
MBX Biosciences Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
MBX Biosciences Inc
NASDAQ:MBX
407.6m USD 0 -5.5 -2.1 -2
US
Eli Lilly and Co
NYSE:LLY
721.7B USD 14.7 65 34.9 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
392.1B USD 4.3 17.3 13.2 17.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.2 18 12.5 14.3
CH
Roche Holding AG
SIX:ROG
204.4B CHF 3.4 24.7 9.3 10.9
CH
Novartis AG
SIX:NOVN
182.9B CHF 4.3 17.7 10.5 14
UK
AstraZeneca PLC
LSE:AZN
159.9B GBP 3.9 27.6 130.6 196.9
US
Merck & Co Inc
NYSE:MRK
205.1B USD 3.2 11.8 8.7 10.6
IE
Endo International PLC
LSE:0Y5F
183.8B USD 79.3 -62.9 292.4 733.2
US
Pfizer Inc
NYSE:PFE
139.7B USD 2.2 17.7 7.6 10.7
P/E Multiple
Earnings Growth PEG
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average P/E: 25
Negative Multiple: -5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
65
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.3
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18
18%
1
CH
Roche Holding AG
SIX:ROG
24.7
32%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.6
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.8
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.9 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.7
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average EV/EBITDA: 436.6
Negative Multiple: -2.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.9
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.2
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average EV/EBIT: 1 874.8
Negative Multiple: -2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
196.9
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.6
11%
1
IE
E
Endo International PLC
LSE:0Y5F
733.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.7
10%
1.1